Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 21st 2015

New FDA Nominee May Face Challenges for His Pharma Ties

Surabhi Dangi-Garimella, PhD

A report in The New York Times identifies challenges that could be raised based on Califf's past associations with the drug industry.

September 20th 2015

About Half with Cancer Want to Discuss Care Costs with Physician, But Fewer Do, Study Finds

Rising costs in cancer care, especially for new therapies, have gained attention in recent years. However, a study just published in The American Journal of Managed Care finds about half of patients are interested in discussing cost on the front end, but only a minority actually have a cost discussion with their oncologist.

September 20th 2015

Dr Clifford Goodman Peers 20 Years Into the Future of NCCN

As the National Comprehensive Cancer Network (NCCN) celebrates 20 years, Clifford Goodman, PhD, takes a look at how NCCN will evolve after another 20 years, including constant streaming of real-time data and more patient involvement.

September 19th 2015

This Week in Managed Care: September 19, 2015

September 18th 2015

Tumor Response Signature to Bevacizumab Recognized in HER2-Negative Breast Cancer

Surabhi Dangi-Garimella, PhD

A collaborative team of researchers have been able to identify a gene signature that can predict how HER2-negative breast cancer patients would respond to treatment with bevacizumab.

September 18th 2015

NIH Approves Blueprint for Obama's Precision Medicine Initiative

Surabhi Dangi-Garimella, PhD

The path to President Obama's Precision Medicine Initiative has been paved as is evident from a report released by a Working Group convened by the National Institutes of Health.

September 17th 2015

MAF Regulates Bone Metastases in Breast Cancer

Surabhi Dangi-Garimella, PhD

Scientists in Spain have identified gene mutations that trigger bone metastasis in breast cancer patients.

September 17th 2015

The Cost Conundrum in Cancer Care

Surabhi Dangi-Garimella, PhD

At the recently held NCCN healthcare policy summit in Washington, DC, experts delved into various models being evaluated to reduce healthcare utilization in oncology care.

September 16th 2015

An Open Discussion on Value in Oncology Care at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD

Healthcare policy makers, payers, medical centers, and patient representatives shared the dais as they discussed The Value Proposition in oncology.

September 16th 2015

Bim Expression Could Predict Patient Response to PD-1 Blockade, Mayo Clinic Study Finds

Surabhi Dangi-Garimella, PhD

Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.

September 16th 2015

Participating Faculty: Management of Advanced/Metastatic Melanoma: New and Emerging Treatment Pathways, Therapies, and Challenges [CPE]

September 15th 2015

Cancer Drugs Driving 340B Growth Even More Than Understood, Report Finds

Mary K. Caffrey

The report, commissioned by the Community Oncology Alliance, finds that Medicare Part B cancer drug spending rose 123% in 340B hospitals from 2010 to 2013, but only 31% in non-340B hospitals; it fell 5% in community practices in the same period.

September 15th 2015

Interoperability Important for Better Outcomes: ASCO to Congress

AJMC Staff

The American Society of Clinical Oncology has urged Congress to recognize the impact of barriers to interoperability of electronic health records on patient outcomes.

September 15th 2015

In Conversation With an Oncologist: 340B and Its Impact on the Community

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.

September 14th 2015

Demographic Factors Influence Survival in Younger Patients With Leukemia

Surabhi Dangi-Garimella, PhD

The study, published in the journal Cancer, found that non-biological factors are as important as biological variables in shaping outcomes in young patients with leukemia.

September 14th 2015

Dr Peter Bach Explains How Increasing Drug Prices Stifle Innovation

The ability to charge increasingly higher prices for drugs that already have competition on the market is stifling innovation and wasting resources and human subjects, according to Peter Bach, MD, MAPP, director of Memorial Sloan Kettering Cancer Center's Center for Health Policy and Outcomes.

September 14th 2015

California "Aid-in-Dying" Bill Awaits Governor's Decision

Mary K. Caffrey

Supporters say the bill would bring choice and dignity to those suffering, while opponents say the poor will be pressured by family members and heirs to take their lives because healthcare is too expensive.

September 14th 2015

Care Access, Centers of Excellence, and the ACA: Expert Interchange at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD

Healthcare policy experts gathered in Washington, DC, to discuss access, cost, and the definition of value in oncology care.

September 13th 2015

Dr Joseph Alvarnas Addresses Rising Medical Costs

Healthcare practitioners are well aware that the rising cost of medical advances may affect their ability to deliver great care to all their patients, but there are ways they can address the issue, said Joseph Alvarnas, MD, the editor-in-chief of Evidence-Based Oncology.

September 11th 2015

Immune Treatments in Cancer Need Additional Vigilance and Earlier Recognition

Surabhi Dangi-Garimella, PhD

An abstract presented at the 16th World Conference on Lung Cancer presented results from a study that monitored irAEs resulting from treatment with immune checkpoint inhibitors.

September 10th 2015

Study Identifies Actionable Mutations in Young Lung Cancer Patients

Surabhi Dangi-Garimella, PhD

Presented at the ongoing World Conference on Lung Cancer, the trial has identified 7 actionable genomic alterations in lung cancer patients under 40 years of age.

September 10th 2015

Kim Thiboldeaux Explains Patient Misconceptions of Cancer Clinical Trials

Kim Thiboldeaux, chief executive officer of the Cancer Support Community, discusses the importance of providing strong community support, the misconceptions of clinical trials, and creating a tailored care plan.

September 10th 2015

ASCO Submits Comments on the Proposed Medicare Physician Fee Schedule Rules

Surabhi Dangi-Garimella, PhD

At the end of CMS' comment period, the American Society of Clinical Oncology submitted its comments and recommendations for the proposed changes.

September 9th 2015

CalPERS Successfully Implemented Reference Payment to Save on Colonoscopy Costs

Surabhi Dangi-Garimella, PhD

The California Public Employees' Retirement System saved $7 million on screening colonoscopies during a 2-year period following implementation of reference pricing.

September 9th 2015

FDA Grants Priority Review for Alectinib in Advanced NSCLC Resistant to Crizotinib

Surabhi Dangi-Garimella, PhD

The drug, approved in Japan last year, had been granted Breakthrough Therapy designation by the FDA.

September 8th 2015

Preliminary Results Promising for Opdivo-Yervoy as First-Line in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

With a new dosing schedule, low toxicity and a PD-L1 expression-driven response was observed.

September 8th 2015

CMS Changes to Physician Fee Schedule Face Resistance From Radiation Oncologists

Surabhi Dangi-Garimella, PhD

With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.

September 7th 2015

CVS: Taking Tobacco From Stores Prompted Quit Attempts; Sales of Cigarettes Dropped

Mary K. Caffrey

Data in study show removal of tobacco from stores led to surge in purchase of nicotine patches.

September 7th 2015

Keytruda Gains NICE Approval While Kadcyla Fails

Surabhi Dangi-Garimella, PhD

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

September 7th 2015

Dr Amy Davidoff Examines Factors Influencing Patient Treatment Decisions in Cancer Care

For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health

...

123 124 125 126 127 128 129 130 131

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions